Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*Sophie Georgin‐Lavialle, Thomas Cluzeau, S. Vinzio et al.|British Journal of Dermatology|2021Cited by 414
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort studyMarie Kostine, Thierry Schaeverbeke, L. Rouxel et al.|Annals of the Rheumatic Diseases|2017Cited by 302
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Thierry Schaeverbeke, Eleonora Mauric et al.|European Journal of Cancer|2021Cited by 93
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registryBenjamin De Valence, Mikaël Ebbo, M. Delaune et al.|Annals of the Rheumatic Diseases|2023Cited by 70
Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 casesÈve Zakine, C. Deligny, Loula Papageorgiou et al.|Journal of the American Academy of Dermatology|2022Cited by 67